• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Fanatics Announces Appointment of Lydia Jett and Jonathan Mildenhall to Board of Directors

    5/5/22 8:30:00 AM ET
    $CPNG
    $GH
    $OZON
    $TXG
    Catalog/Specialty Distribution
    Consumer Discretionary
    Medical Specialities
    Health Care
    Get the next $CPNG alert in real time by email

    Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform

    Separately, Fanatics releases its first environmental, social and governance (ESG) report

    Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising and building some of the world's most influential tech companies and consumer brands.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005104/en/

    Lydia Jett (Photo: Business Wire)

    Lydia Jett (Photo: Business Wire)

    Both well-admired leaders will play vital roles in uncovering and amplifying opportunities for Fanatics to continue scaling its businesses worldwide, which currently include licensed merchandise and e-commerce, trading cards and collectibles, digital collectibles and NFT's, and online sports betting and iGaming.

    "Fanatics is in the midst of incredible transformation and the deep expertise and insight that Lydia and Jonathan both bring to the board will be vital as we unlock a new digital experience for sports fans globally," said Fanatics CEO Michael Rubin. "They are both visionaries in their respective fields that will provide invaluable support and guidance as we continue building a revolutionary sports platform."

    Lydia, the first female to hold the title of Managing Partner within SoftBank's Vision Fund, has nearly twenty years of experience investing in and serving on the boards of market leading technology businesses. Since SoftBank's initial backing of Fanatics in 2017 - when the firm led a more than $1 billion investment round - she has been a driving force behind the company's innovation across the licensed sports industry and recent expansion beyond merchandise.

    "Over my past five years with the Fanatics management team, I have seen an extraordinary focus, agility and creativity targeted towards fundamentally remaking an industry to better serve its ultimate customers: leagues, athletes and fans," said Jett. "As we enter the next half decade together, Fanatics is better positioned than ever to be a driving force behind improving a global sports fan's experience across the digital and physical world."

    Jonathan, a globally respected marketing and advertising professional, co-founded the influential brand building and marketing consultancy firm, TwentyFirstCenturyBrand, and serves as Executive Chairman. Mildenhall also previously served as CMO of Airbnb from 2014 to 2018, a time in which the company's valuation increased from $1 billion to more than $31 billion. Mildenhall's expertise is defining company purpose and values, brand strategy and digital transformation, assets that will be invaluable to Fanatics as the company continues to build its brand globally and unlock opportunities to engage with sports fans across current and emerging verticals.

    "Over the last six months I have gotten to know Michael, his executive team, and the Fanatics business in a deep and substantial way," said Mildenhall. "The deeper my understanding of the incredible opportunity ahead the more irresistible the idea of joining the board became. Fanatics will become a culturally significant global brand that will define this and further generations to come."

    In addition to Fanatics, both Lydia and Jonathan serve as members on several company boards. Jett has represented SoftBank on the boards of global internet, e-commerce and blockchain companies including Coupang (NYSE:CPNG), Flipkart, GoTo (IDX: GOTO) and Weee!, and Mildenhall serves on the board of Peloton, Northern Star SPAC, and GoFundMe.

    Separate from these board appointments, Fanatics recently released its first environmental, social and governance (ESG) report. The report, which spans 2020 and 2021, covers ESG efforts across several initiatives, including the company's customer-centric approach, philanthropic endeavours, Fanatics' inclusion, diversity, equity, and advocacy (IDEA) model, sustainability, labor and human rights, and much more.

    To read the full report: https://www.fanaticsinc.com/global-impact

    About Lydia Jett

    Lydia Jett is a Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA) where she has led and represented SoftBank on the Board of Directors of many of the firm's global investments in consumer internet, e-commerce and blockchain companies including: Coupang (NYSE:CPNG), Fanatics, Flipkart, GoTo (IDX: GoTo), LTK, Misfits Market, Pacaso, The Sandbox, Veho and Weee!

    Prior to SBIA, Lydia was a senior member of the investment team at SoftBank Group Corp International where she led SBGI's investments in Guardant Health (NASDAQ:GH) and 10X Genomics (NASDAQ:TXG). Previously, Lydia was a Vice President at M/C Partners, a growth equity firm, and an Associate at Goldman Sachs in the Principal Investment Area where she invested across media and technology sectors. She started her career at JPMorgan.

    In addition, Lydia is an independent board member of Ozon (NASDAQ:OZON), where she serves on the Audit, Compensation and Nomination and Governance Committees and has published work in Fast Company. Lydia is a graduate of the Stanford Graduate School of Business, the London School of Economics and Smith College, and has been recognized as one of Fortune's "Most Powerful Women."

    About Jonathan Mildenhall

    Jonathan Mildenhall co-founded TwentyFirstCenturyBrand, the influential brand-building and marketing consultancy firm, in 2018, and serves as the company's Executive Chairman. He is also a board member on several company boards, including Peloton, Northern Star SPAC, and GoFundMe, and he serves as the Co-Chair of non-profit College Track's Los Angeles Advisory Board. Prior to co-founding TwentyFirstCenturyBrand, Mildenhall served as CMO of Airbnb from 2014 to 2018, during which time Airbnb's valuation increased from $1 billion to more than $31 billion.

    Prior to Airbnb, Mildenhall led The Coca-Cola Company's marketing initiatives as VP of global advertising strategy and content excellence from 2007 to 2013, and as SVP of integrated marketing communication and design excellence from 2013 to 2014. Earlier in his career, Mildenhall served in various management positions in advertising. Mildenhall holds an HND in Business and Finance from The Manchester Metropolitan University. He completed the Advanced Management Program at Harvard Business School and holds an Honorary Doctorate in Business Administration from The Manchester Metropolitan University. Mildenhall lives in Los Angeles with his husband Mirco and their children Dominica and Oliver.

    He has been named to the Financial Times "EMpower 100 Ethnic Minority Leaders" list, has won the AdWeek Brand Genius award, and has been recognized on the Business Insider list of the "Top 50 Most Innovative CMOs in the World."

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005104/en/

    Get the next $CPNG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPNG
    $GH
    $OZON
    $TXG

    CompanyDatePrice TargetRatingAnalyst
    Guardant Health Inc.
    $GH
    4/10/2025$55.00Outperform
    Mizuho
    Coupang Inc.
    $CPNG
    2/26/2025$28.50Hold → Buy
    Deutsche Bank
    10x Genomics Inc.
    $TXG
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    Guardant Health Inc.
    $GH
    1/23/2025$60.00Overweight
    Barclays
    Coupang Inc.
    $CPNG
    10/7/2024$30.00Underperform → Outperform
    Bernstein
    Coupang Inc.
    $CPNG
    9/4/2024$18.00 → $31.00Hold → Outperform
    CLSA
    10x Genomics Inc.
    $TXG
    9/3/2024$35.00Outperform
    Leerink Partners
    10x Genomics Inc.
    $TXG
    7/22/2024$24.00Hold → Buy
    Jefferies
    More analyst ratings

    $CPNG
    $GH
    $OZON
    $TXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      2/25/25 5:22:04 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Greenoaks Capital Partners Llc bought $54,632,027 worth of Class A Common Shares (2,250,199 units at $24.28) (SEC Form 4)

      4 - Coupang, Inc. (0001834584) (Issuer)

      11/12/24 9:15:38 PM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Director Greenoaks Capital Partners Llc bought $6,881,320 worth of shares (300,000 units at $22.94) (SEC Form 4)

      4 - Coupang, Inc. (0001834584) (Issuer)

      8/23/24 9:00:21 PM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary

    $CPNG
    $GH
    $OZON
    $TXG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 30, 2024 - FDA Roundup: July 30, 2024

      For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

      7/30/24 3:38:18 PM ET
      $GH
      Medical Specialities
      Health Care
    • May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

      For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

      5/28/21 1:05:48 PM ET
      $AMGN
      $GH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
    • May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

      For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

      5/21/21 12:50:51 PM ET
      $JNJ
      $GH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities

    $CPNG
    $GH
    $OZON
    $TXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Joyce Meghan V. converted options into 66 shares, increasing direct ownership by 0.85% to 7,846 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      5/5/25 9:03:07 PM ET
      $GH
      Medical Specialities
      Health Care
    • Co-Chief Executive Officer Talasaz Amirali sold $5,936,572 worth of shares (120,716 units at $49.18), decreasing direct ownership by 5% to 2,188,740 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      5/5/25 9:02:01 PM ET
      $GH
      Medical Specialities
      Health Care
    • VP, Search and Recommendations Kolari Pranam sold $222,926 worth of shares (9,347 units at $23.85), decreasing direct ownership by 5% to 177,106 units (SEC Form 4)

      4 - Coupang, Inc. (0001834584) (Issuer)

      5/2/25 9:16:10 PM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary

    $CPNG
    $GH
    $OZON
    $TXG
    SEC Filings

    See more
    • SEC Form 144 filed by Coupang Inc.

      144 - Coupang, Inc. (0001834584) (Subject)

      5/8/25 9:00:03 PM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary
    • 10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - 10x Genomics, Inc. (0001770787) (Filer)

      5/8/25 4:05:10 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

      SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      5/7/25 10:55:48 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CPNG
    $GH
    $OZON
    $TXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Guardant Health Inc.

      SC 13G - Guardant Health, Inc. (0001576280) (Subject)

      11/13/24 7:34:17 PM ET
      $GH
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Coupang Inc.

      SC 13G/A - Coupang, Inc. (0001834584) (Subject)

      11/12/24 4:30:29 PM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Coupang Inc.

      SC 13G/A - Coupang, Inc. (0001834584) (Subject)

      11/8/24 2:52:10 PM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary

    $CPNG
    $GH
    $OZON
    $TXG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 10x Genomics Reports First Quarter 2025 Financial Results

      PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As

      5/8/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Guardant Health to Participate in Upcoming Investor Conferences

      Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BofA Securities 2025 Healthcare Conference in Las Vegas, NV Fireside chat on Wednesday, May 14th at 3:40 p.m. Pacific Time Jefferies Global Healthcare Conference in New York, NY Fireside chat on Wednesday, June 4th at 2:35 p.m. Eastern Time Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL Fireside chat on Monday, June 9th at 10:00 a.m. Eastern Time Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at: www.guardanthealth.com.

      5/8/25 4:05:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year

      Today TIME named to its 2025 TIME100 Health list co-CEOs Helmy Eltoukhy and AmirAli Talasaz of Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company. The list recognizes and honors the top 100 most influential people in global health this year. "The inclusion on TIME100 Health's list is more than a personal honor," said AmirAli Talasaz, Guardant Health co-CEO. "It is a recognition of the incredible technology that our Guardant team has built with the Shield blood test for colorectal cancer and Shield's ability to save lives around the world. The result of over 10 years of research and development, the Shield blood test has the promise to detect multiple cancers at an earl

      5/8/25 9:20:00 AM ET
      $GH
      Medical Specialities
      Health Care

    $CPNG
    $GH
    $OZON
    $TXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Guardant Health with a new price target

      Mizuho initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $55.00

      4/10/25 12:41:47 PM ET
      $GH
      Medical Specialities
      Health Care
    • Coupang upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded Coupang from Hold to Buy and set a new price target of $28.50

      2/26/25 7:03:12 AM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary
    • 10x Genomics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded 10x Genomics from Outperform to Market Perform and set a new price target of $12.00 from $25.00 previously

      2/13/25 7:11:34 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CPNG
    $GH
    $OZON
    $TXG
    Financials

    Live finance-specific insights

    See more
    • 10x Genomics Reports First Quarter 2025 Financial Results

      PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As

      5/8/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Coupang Announces Results for First Quarter 2025

      Net Revenues of $7.9 billion, up 11% YoY and 21% on an FX-neutral basis Gross Profit of $2.3 billion, up 20% YoY and 31% on an FX-neutral basis Operating income of $154 million, up $114 million Operating Cash Flow of $2.0 billion and Free Cash Flow of $1.0 billion for the trailing twelve months Coupang, Inc. (NYSE:CPNG) today announced financial results for its first quarter ended March 31, 2025. Q1 2025 Consolidated Highlights: Net revenues were $7.9 billion, up 11% YoY on a reported basis and 21% YoY on an FX-neutral basis. Gross profit increased 20% YoY and 31% YoY on an FX-neutral basis to $2.3 billion. Gross profit margin was 29.3%, an improvement of 217 bps YoY. Operating i

      5/6/25 4:05:00 PM ET
      $CPNG
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

      Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25% Screening revenue of $5.7 milli

      4/30/25 4:05:00 PM ET
      $GH
      Medical Specialities
      Health Care

    $CPNG
    $GH
    $OZON
    $TXG
    Leadership Updates

    Live Leadership Updates

    See more
    • Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

      Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. This press release

      3/5/25 8:05:00 AM ET
      $GH
      Medical Specialities
      Health Care
    • Roberto A. Mignone Joins Guardant Health Board of Directors

      Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look

      10/24/24 5:05:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • 10x Genomics Announces Senior Leadership Changes

      PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer

      8/8/24 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials